TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29795315

Group type: EXPERIMENTAL
Intervention: Anticonvulsants with sedation-analgesia (SA)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Anticonvulsants without sedation-analgesia (SA)
Number of subjects: 208

Group type: COMPARATOR
Intervention: No exposure to SA or anticonvulsants
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Sedation-analgesia (SA) alone
Number of subjects: 208
Study: 27354480

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 24118106

Group type: EXPERIMENTAL
Intervention: Psychoeducational DVD intervention for cachexia management
Number of subjects: 200
Study: 22229972

Group type: EXPERIMENTAL
Intervention: CS-occlusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 19923089

Group type: EXPERIMENTAL
Intervention: TACE combined with percutaneous lipiodol and anti-cancer agent injection into the tumor (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TACE (Group A)
Number of subjects: 40
Study: 17600466

Group type: EXPERIMENTAL
Intervention: Rituximab + chemotherapy (CEOP)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Chemotherapy (CEOP)
Number of subjects: 204
Study: 15610371

Group type: EXPERIMENTAL
Intervention: Amino acid-based elemental milk formula for 6 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pre-existing formulae (placebo) for 6 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Amino acid-based elemental milk formula
Number of subjects: 15
Study: 11429357

Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric ropivacaine (18 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine (12 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 9678820

Group type: EXPERIMENTAL
Intervention: Mebeverine (135 mg t.d.s.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 9
Study: 8036831

Group type: COMPARATOR
Intervention: EcSf2a-2 vaccine (doses ranging from 2.3 to 9.0 x 10(8) CFU, given on days 0, 3, 14, and 17)
Number of subjects: 244

Group type: COMPARATOR
Intervention: EcSf2a-2 vaccine
Number of subjects: 244
Study: 2498397

Group type: EXPERIMENTAL
Intervention: Hexetidine/zinc citrate toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2% Triclosan toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amyloglucosidase/glucose oxidase toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium fluoride/sodium monofluorophosphate toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fluoride toothpaste
Number of subjects: 0
Study: 6407504

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (mean dose 101 mg/day)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose 127 mg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 31771387

Group type: EXPERIMENTAL
Intervention: Gait with sub-motor threshold NMES
Number of subjects: 22

Group type: COMPARATOR
Intervention: Gait with sham NMES
Number of subjects: 22
Study: 30884111

Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Autogenous Block Graft (ABG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: ABG
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 28766650

Group type: EXPERIMENTAL
Intervention: Addition of non-photoactive tertiary polymer phase (PMMA) in the binary BHJ blend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Binary BHJ blend (P3HT:fullerene) without PMMA
Number of subjects: 0
Study: 25655884

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sedentary behaviors
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Low-intensity activities
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Moderate-intensity lifestyle activities
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Moderate- to vigorous-intensity ambulatory activities
Number of subjects: 95
Study: 24839916

Group type: EXPERIMENTAL
Intervention: 600 mg/day ferrous fumarate plus 1mg/day folic acid (FFFA group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 600 mg/day ferrous fumarate alone (FF group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: 600 mg/day ferrous fumarate (both groups)
Number of subjects: 112
Study: 21857244

Group type: EXPERIMENTAL
Intervention: Oral ketamine (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral fentanyl (group C)
Number of subjects: 150
Study: 21118495

Group type: EXPERIMENTAL
Intervention: ezetimibe + atorvastatin 40 mg
Number of subjects: 579

Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 579
Study: 17658249

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol fumarate 12 microg twice daily for 14 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16363240

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg twice daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (normal pregnancies)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Enoxaparin (both dosages)
Number of subjects: 87
Study: 12523169

Group type: EXPERIMENTAL
Intervention: rhEPO (4000 units, 3 times a week for 4 months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (haematocrit values above 28%, not treated with rhEPO)
Number of subjects: 65
Study: 9456244

Group type: EXPERIMENTAL
Intervention: Quantitative fluorescence image analysis (QFIA) of DNA ploidy and nuclear morphology
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Traditional cytology
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: Combination of QFIA and traditional cytology
Number of subjects: 1331

Group type: EXPERIMENTAL
Intervention: QFIA variables
Number of subjects: 1331

Group type: COMPARATOR
Intervention: Cytological diagnoses
Number of subjects: 1331
Study: 8077815

Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 24
Study: 2806891

Group type: EXPERIMENTAL
Intervention: Navane (thiothixene)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Haldol
Number of subjects: 17
Study: 72240

Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30959472

Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (ice chips) during oxaliplatin infusion
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard-of-care treatment (control)
Number of subjects: 62
Study: 28650086

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolysis (CDT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (IV tPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis
Number of subjects: 0
Study: 25646792

Group type: EXPERIMENTAL
Intervention: Infacort (oral hydrocortisone granules with taste masking)
Number of subjects: 0
Study: 23581723

Group type: EXPERIMENTAL
Intervention: Children's beliefs about the objectivity of social categories
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Children's beliefs about race and ethnicity
Number of subjects: 109
Study: 21807324

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 19500848

Group type: EXPERIMENTAL
Intervention: hh‐DCT
Number of subjects: 50

Group type: COMPARATOR
Intervention: sl‐DCT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: hh‐DCT and sl‐DCT
Number of subjects: 50
Study: 17511176

Group type: EXPERIMENTAL
Intervention: Dexamethasone and Cefuroxime Sodium
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cefuroxime Sodium
Number of subjects: 43
Study: 15505499

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h/24 hrs for 6 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 16
Study: 11148592

Group type: EXPERIMENTAL
Intervention: Neighborhood-based educational activities, dissemination of health education materials, media campaign, continuing medical education seminars for physicians
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Greater exposure to intervention elements
Number of subjects: 788

Group type: COMPARATOR
Intervention: Control group (women in Los Angeles and Orange Counties)
Number of subjects: 788
Study: 9672169

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 3 MU tiw for 6 months
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 6 MU tiw for 8 weeks followed by down-titration (3,1 MU tiw)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Interferon-alpha 6 MU tiw
Number of subjects: 336

Group type: COMPARATOR
Intervention: Interferon-alpha 3 MU tiw
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Week 4 HCV RNA not detectable
Number of subjects: 336
Study: 8062564

Group type: EXPERIMENTAL
Intervention: Propofol (mean loading dose 0.24 mg/kg; mean maintenance dose 0.76 mg/kg/hr)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Midazolam (mean loading dose 0.012 mg/kg; mean maintenance dose 0.018 mg/kg/hr)
Number of subjects: 84
Study: 3248129

Group type: EXPERIMENTAL
Intervention: Acetate buffered fluid
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bicarbonate buffered fluid
Number of subjects: 8
Study: 31983236

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study: 31244297

Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM) implemented in four stages during four sessions of 20-40 minutes
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study: 28376642

Group type: EXPERIMENTAL
Intervention: Neck irradiation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 26172928

Group type: EXPERIMENTAL
Intervention: FRAX® tool assessment for clinical risk factors of OP
Number of subjects: 0
Study: 24292619

Group type: EXPERIMENTAL
Intervention: HEPHAISTOS orthosis
Number of subjects: 11
Study: 21562061

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (Rsg)
Number of subjects: 74
Study: 19430757

Group type: EXPERIMENTAL
Intervention: Preoperative pain
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Acute preoperative pain
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Chronic preoperative pain
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Well-being
Number of subjects: 165
Study: 16836761

Group type: EXPERIMENTAL
Intervention: Preventive Care Checklist Forms used in intervention clinics
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Control group (no checklist form)
Number of subjects: 1117
Study: 12734789

Group type: EXPERIMENTAL
Intervention: Moderate exercise for 60 min at 50% of VO(2) max
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting session (no exercise)
Number of subjects: 6
Study: 10814693

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 55
Study: 9186825

Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin combination therapy (dosage as for monotherapy) for 6 months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Interferon monotherapy (3 MU 3x/week) for 6 months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Ribavirin monotherapy (1000-1200 mg/day) for 6 months
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 186
Study: 8355975

Group type: EXPERIMENTAL
Intervention: BCG treatment
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control (transurethral resection)
Number of subjects: 170
Study: 3526803

Group type: EXPERIMENTAL
Intervention: Bardex Urinary Drainage System
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine system (silicone‐coated 16F Latex Foley catheter)
Number of subjects: 40
Study: 27489004

Group type: EXPERIMENTAL
Intervention: Household Food Insecurity (HFI)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Depressive symptoms (measured by PHQ-8)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Anxiety symptoms (measured by PROMIS-short)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Diabetes distress (measured by PAID-5)
Number of subjects: 121
Study: 24990032

Group type: EXPERIMENTAL
Intervention: ALS subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Remaining ALS subjects after excluding four with very weak maximum force
Number of subjects: 20
Study: 22705016

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 400
Study: 20521308

Group type: EXPERIMENTAL
Intervention: Tailored cognitive-behavioral therapy (CBT) and exercise training (16 sessions over 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0
Study: 18668592

Group type: EXPERIMENTAL
Intervention: Abetimus (100 mg/week for up to 22 months)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 15806043

Group type: EXPERIMENTAL
Intervention: DPOAE-grams in tinnitus ears
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy nontinnitus ears
Number of subjects: 32
Study: 12897643

Group type: EXPERIMENTAL
Intervention: Safinamide 2 mg/kg oral load
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9887110

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) supplementation (17.8 micromol Cr/day, 924 microg Cr/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 18
Study: 8890308

Group type: EXPERIMENTAL
Intervention: Motor unit activity during elbow flexion and extension with varying deceleration magnitudes
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motor unit activity during elbow flexion and extension with constant acceleration magnitude
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motor unit activity during extension movements
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motor unit activity during flexion movements
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Motor unit activity during agonist and antagonist functions
Number of subjects: 47
Study: 1706506

Group type: EXPERIMENTAL
Intervention: VVIR pacing
Number of subjects: 21

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 21
Study: 6513433

Group type: EXPERIMENTAL
Intervention: Verapamil (40 mg doses p.o./day continuously)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (61 patients treated without additional verapamil therapy)
Number of subjects: 22
Study: 30810500

Group type: EXPERIMENTAL
Intervention: Protein (≥30 g of high-quality protein/meal)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (traditional weight loss regimen)
Number of subjects: 39
Study: 29956495

Group type: EXPERIMENTAL
Intervention: Self-regulation with small changes (200 kcal/day deficit)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Self-regulation with large changes (5-10 lb weight loss)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Self-guided control
Number of subjects: 599
Study: 27426466

Group type: EXPERIMENTAL
Intervention: Suction drain used during operation (drain group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: No suction drain applied (no drain group)
Number of subjects: 86
Study: 25415455

Group type: EXPERIMENTAL
Intervention: Combined intervention package (life-skills and health education, vocational training, micro-grants, social supports)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Life-skills and health education alone
Number of subjects: 315
Study: 22494013

Group type: EXPERIMENTAL
Intervention: High stimulation (HS) spinal cord stimulation therapy, controlled with a programmer for a minimum of two hours four times daily.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Low stimulation (LS) spinal cord stimulation therapy, received above the paresthesia threshold for one min once daily.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Comparison between HS and LS groups.
Number of subjects: 68
Study: 20028832

Group type: EXPERIMENTAL
Intervention: Stress Reduction Treatment (SRT)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual Cardiac Care
Number of subjects: 304
Study: 17916545

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily plus lansoprazole 30 mg once daily
Number of subjects: 1045
Study: 16254090

Group type: EXPERIMENTAL
Intervention: Target believed to be dead
Number of subjects: 0

Group type: COMPARATOR
Intervention: Target believed to be alive
Number of subjects: 0
Study: 12709721

Group type: EXPERIMENTAL
Intervention: CGRP (3, 10, and 30 ng x min(‐1) x dL(‐1) forearm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CGRP with L‐NMMA (a nitric oxide‐synthase inhibitor)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CGRP with indomethacin (a cyclooxygenase inhibitor)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CGRP with tetraethylammonium chloride (TEAC) (a K(+)(Ca)‐channel blocker)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CGRP with glyburide (INN, glibenclamide) (a K(+)(ATP)‐channel blocker)
Number of subjects: 40

Group type: COMPARATOR
Intervention: CGRP with placebo (sodium chloride, 0.9%)
Number of subjects: 40
Study: 10604047

Group type: EXPERIMENTAL
Intervention: SAM patch (50 micrograms/day estradiol)
Number of subjects: 399

Group type: COMPARATOR
Intervention: LR patch (50 micrograms/day estradiol)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: SAM patch
Number of subjects: 399

Group type: COMPARATOR
Intervention: LR patch
Number of subjects: 399
Study: 7729633

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg three times a day) + Amoxicillin (750 mg three times a day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Omeprazole (40 mg three times a day) + Placebo (750 mg three times a day)
Number of subjects: 270

Group type: COMPARATOR
Intervention: H. pylori‐negative patients
Number of subjects: 270

Group type: COMPARATOR
Intervention: H. pylori‐positive patients
Number of subjects: 270
Study: 2202163

Group type: EXPERIMENTAL
Intervention: 10% cyclosporin in a jelly base
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5% cyclosporin in an ointment base under occlusion
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2
Study: 7408414

Group type: EXPERIMENTAL
Intervention: Naloxone 0.8 mg intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine 15 mg intravenously
Number of subjects: 12
Study: 31694616

Group type: EXPERIMENTAL
Intervention: Healthcare workers training and peer engagement
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control region (Tanga)
Number of subjects: 1800
Study: 26787629

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 000 IU weekly for 8 weeks, then 50 000 IU monthly for 2 months (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 7000 IU daily for 8 weeks, then 12 500 IU weekly for 2 months (group B)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 71
Study: 26031308

Group type: EXPERIMENTAL
Intervention: Tiotropium HandiHaler®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24093855

Group type: EXPERIMENTAL
Intervention: Early cardiology follow-up after AMI
Number of subjects: 533

Group type: COMPARATOR
Intervention: Uninsured status
Number of subjects: 533

Group type: COMPARATOR
Intervention: Cardiologist-driven inpatient medical decision making
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Overall LVEF reassessment
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 533
Study: 22143216

Group type: EXPERIMENTAL
Intervention: Spiritual Care Education Program (SCEP), 2 hours per week for 6 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 81
Study: 19258472

Group type: EXPERIMENTAL
Intervention: Normal BMI (18.5-25)
Number of subjects: 28380

Group type: EXPERIMENTAL
Intervention: Overweight BMI (25-30)
Number of subjects: 28380

Group type: EXPERIMENTAL
Intervention: Obese BMI (30-35)
Number of subjects: 28380

Group type: EXPERIMENTAL
Intervention: Morbidly Obese BMI (>35)
Number of subjects: 28380

Group type: EXPERIMENTAL
Intervention: All BMI categories
Number of subjects: 28380
Study: 16925685

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with a cumulative dose of around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen for 6 months.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15541243

Group type: EXPERIMENTAL
Intervention: Highest tertile of left ventricular sphericity
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Independent predictors of 10-year survival rate
Number of subjects: 825
Study: 12805106

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 23
Study: 9593493

Group type: EXPERIMENTAL
Intervention: SDR plus physical therapy (PT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: SDR plus PT
Number of subjects: 43
Study: 8537612

Group type: EXPERIMENTAL
Intervention: Ceftizoxime and ceftriaxone
Number of subjects: 20
Study: 2244793

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride maintained at an average dose of 200 mg
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Monthly interpersonal psychotherapy
Number of subjects: 128